EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

Sara M Tolaney, Valentina Guarneri, Jae Hong Seo, Josefina Cruz, Miguel Henriques Abreu, Masato Takahashi, Carlos Barrios, Kristi McIntyre, Ran Wei, Maria Munoz, Belen San Antonio, Astra M Liepa und 4 weitere

European Journal of Cancer · 2024-03 · 199 · 113555

DOI: 10.1016/j.ejca.2024.113555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024-03. Verfasst von Sara M Tolaney und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Sara_Tolaney@DFCI.HARVARD.EDU. Hauptthemen laut MEDLINE: Breast Neoplasms, Benzimidazoles. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBenzimidazolesHumansFemaleQuality of LifeAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsPatient Reported Outcome MeasuresDiarrheaErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

AbemaciclibMonarchEPatient-reported outcomeQuality of life

Substanzen

AminopyridinesErb-b2 Receptor Tyrosine KinasesBenzimidazolesabemaciclib

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Sara_Tolaney@DFCI.HARVARD.EDU.
  • Oncology2, Istituto Oncologico Veneto IRCCS, Padua, Italy.
  • Korea University Guro Hospital, Seoul, Republic of Korea.
  • Hospital Universitario de Canarias, Canary Islands, Spain.
  • Department of Medical Oncology, Portuguese Institute of Oncology of Porto, Porto, Portugal.
  • Department of Breast Surgery, Hokkaido University Hospital, Hokkaido, Japan.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Tolaney, S. M., Guarneri, V., Seo, J. H., Cruz, J., Abreu, M. H., Takahashi, M., Barrios, C., McIntyre, K., Wei, R., Munoz, M., Antonio, B. S., Liepa, A. M., Martin, M., Johnston, S. R. D., Kellokumpu-Lehtinen, P. L., & Harbeck, N. (2024). Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. European Journal of Cancer, 199, 113555. https://doi.org/10.1016/j.ejca.2024.113555

Vancouver

Tolaney SM, Guarneri V, Seo JH, Cruz J, Abreu MH, Takahashi M, et al. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. European Journal of Cancer. 2024;199:113555. doi:10.1016/j.ejca.2024.113555

BibTeX
@article{Tolaney2024,
  author = {Tolaney, Sara M and Guarneri, Valentina and Seo, Jae Hong and Cruz, Josefina and Abreu, Miguel Henriques and Takahashi, Masato and Barrios, Carlos and McIntyre, Kristi and Wei, Ran and Munoz, Maria and Antonio, Belen San and Liepa, Astra M and Martin, Miguel and Johnston, Stephen R D and Kellokumpu-Lehtinen, Pirkko-Liisa and Harbeck, Nadia},
  title = {Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {199},
  pages = {113555},
  doi = {10.1016/j.ejca.2024.113555}
}
Kostenlos starten →